Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
DNA Repair (Amst) ; 141: 103735, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39079395

ABSTRACT

DNA replication ensures the complete and accurate duplication of the genome. The traditional approach to analysing perturbation of DNA replication is to use chemical inhibitors, such as hydroxyurea or aphidicolin, that slow or stall replication fork progression throughout the genome. An alternative approach is to perturb replication at a single site in the genome that permits a more forensic investigation of the cellular response to the stalling or disruption of a replication fork. This has been achieved in several organisms using different systems that share the common feature of utilizing the high affinity binding of a protein to a defined DNA sequence that is integrated into a specific locus in the host genome. Protein-mediated replication fork blocking systems of this sort have proven very valuable in defining how cells cope with encountering a barrier to fork progression. In this review, we compare protein-based replication fork barrier systems from different organisms that have been developed to generate site-specific replication fork perturbation.


Subject(s)
DNA Replication , Humans , Animals , DNA/metabolism , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/genetics
2.
PLoS One ; 15(3): e0229017, 2020.
Article in English | MEDLINE | ID: mdl-32130239

ABSTRACT

We have earlier reported that cell-free chromatin (cfCh) particles that are released from dying cells, or those that circulate blood, can readily enter into healthy cells, illegitimately integrate into their genomes and induce dsDNA breaks, apoptosis and intense activation of inflammatory cytokines. We hypothesized that sepsis is caused by cfCh released from dying host cells following microbial infection leading to bystander host cell apoptosis and inflammation which are perpetuated in a vicious cycle with release of more cfCh from dying host cells. To test this hypothesis we used three cfCh inactivating agents namely 1) anti-histone antibody complexed nanoparticles which inactivate cfCh by binding to histones; 2) DNase I which inactivates cfCh by degrading its DNA component, and 3) a novel pro-oxidant combination of Resveratrol and Copper which, like DNase I, inactivates cfCh by degrading its DNA component. Female C57 BL/6 mice, 6-8 weeks old, were administered a single i.p. injection of LPS at a dose of 10 mg/Kg or 20 mg/Kg with or without concurrent treatment with the above cfCh inactivating agents. Administration of cfCh inactivating agents concurrently with LPS resulted in prevention of following pathological parameters: 1) release of cfCh in extra-cellular spaces of brain, lung and heart and in circulation; 2) release of inflammatory cytokines in circulation; 3) activation of DNA damage, apoptosis and inflammation in cells of thymus, spleen and in PBMCs; 4) DNA damage, apoptosis and inflammation in cells of lung, liver, heart, brain, kidney and small intestine; 5) liver and kidney dysfunction and elevation of serum lactate; 6) coagulopathy, fibrinolysis and thrombocytopenia; 7) lethality. We conclude that cfCh that are released from dying host cells in response to bacterial endotoxin represents a global instigator of sepsis. cfCh inactivation may provide a novel approach to management of sepsis in humans.


Subject(s)
Cell Death , Cell-Free Nucleic Acids/metabolism , Chromatin/metabolism , Endotoxins , Sepsis/metabolism , Sepsis/pathology , Animals , Cell Death/drug effects , Cell Death/physiology , Chromatin/pathology , Chromatin/physiology , Copper/administration & dosage , Cytokines/metabolism , DNA Damage/drug effects , Deoxyribonuclease I/metabolism , Deoxyribonuclease I/therapeutic use , Female , Histones/metabolism , Inflammation Mediators/metabolism , Lipopolysaccharides , Mice , Mice, Inbred C57BL , Nanoparticles/therapeutic use , Resveratrol/administration & dosage , Sepsis/chemically induced , Sepsis/prevention & control
3.
Cell Death Dis ; 9(12): 1142, 2018 11 15.
Article in English | MEDLINE | ID: mdl-30442925

ABSTRACT

Radiation-induced bystander effect (RIBE) is a poorly understood phenomenon wherein non-targeted cells exhibit effects of radiation. We have reported that cell-free chromatin (cfCh) particles that are released from dying cells can integrate into genomes of surrounding healthy cells to induce DNA damage and inflammation. This raised the possibility that RIBE might be induced by cfCh released from irradiated dying cells. When conditioned media from BrdU-labeled irradiated cells were passed through filters of pore size 0.22 µm and incubated with unexposed cells, BrdU-labeled cfCh particles could be seen to readily enter their nuclei to activate H2AX, active Caspase-3, NFκB, and IL-6. A direct relationship was observed with respect to activation of RIBE biomarkers and radiation dose in the range of 0.1-0 Gy. We confirmed by FISH and cytogenetic analysis that cfCh had stably integrated into chromosomes of bystander cells and had led to extensive chromosomal instability. The above RIBE effects could be abrogated when conditioned media were pre-treated with agents that inactivate cfCh, namely, anti-histone antibody complexed nanoparticles (CNPs), DNase I and a novel DNA degrading agent Resveratrol-copper (R-Cu). Lower hemi-body irradiation with γ-rays (0.1-50 Gy) led to activation of H2AX, active Caspase-3, NFκB, and IL-6 in brain cells in a dose-dependent manner. Activation of these RIBE biomarkers could be abrogated by concurrent treatment with CNPs, DNase I and R-Cu indicating that activation of RIBE was not due to radiation scatter to the brain. RIBE activation was seen even when mini-beam radiation was delivered to the umbilical region of mice wherein radiation scatter to brain was negligible and could be abrogated by cfCh inactivating agents. These results indicate that cfCh released from radiation-induced dying cells are activators of RIBE and that it can be prevented by treatment with appropriate cfCh inactivating agents.


Subject(s)
Chromatin/genetics , Inflammation/drug therapy , Radiation Injuries/drug therapy , Resveratrol/pharmacology , Animals , Bystander Effect/drug effects , Bystander Effect/radiation effects , Caspase 3/genetics , Cell-Free System/drug effects , Cell-Free System/radiation effects , Chromatin/drug effects , Chromatin/radiation effects , Copper/pharmacology , Culture Media, Conditioned/pharmacology , DNA Damage/radiation effects , Deoxyribonuclease I/genetics , Disease Models, Animal , Gamma Rays/adverse effects , Histones/genetics , Humans , Inflammation/genetics , Inflammation/pathology , Interleukin-6/genetics , Mice , NF-kappa B/genetics , Radiation Injuries/genetics , Radiation Injuries/pathology
SELECTION OF CITATIONS
SEARCH DETAIL